In a building adjacent to the technology transfer office at Indiana University, John Hurrell is hoping to create a new kind of proteomics consortium. Unlike its counterpart in Michigan, a multi-university distributed research program funded with money from the state’s tobacco settlement, Hurrel’s Indiana Proteomics Consortium is working directly with big pharma — in the form of Eli Lilly, the fifth largest pharma company in the US.